MedTrace Logo

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

NCT02260531 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-05-20

Study results available
· View outcomes & findings →

Summary

This research study is evaluating the effectiveness of the drug called cabozantinib (alone or in combination with trastuzumab) as a possible treatment for advanced breast cancer in which the cancer has spread to the brain.

Conditions

Interventions

DRUG

Cabozantinib

DRUG

Trastuzumab

Sponsors & Collaborators

Principal Investigators

  • Sara Tolaney, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2019-01-04
Completion
2020-03-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02260531 on ClinicalTrials.gov